Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.65 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1177256 | 0.98 | HPGD (0.64) | HPGDHIF1AEPAS1ALDH1A1HRH3 | |
| SCHEMBL13266931 | 0.95 | HPGD (0.61) | HPGDHIF1AEPAS1ALDH1A1HRH3 | |
| SCHEMBL28137839 | 0.95 | AOC3 (0.62) | HPGDHIF1AEPAS1ALDH1A1HRH3 | |
| SCHEMBL254490 | 0.95 | HRH3 (0.72) | HPGDHIF1AEPAS1ALDH1A1HRH3 | |
| SCHEMBL3019730 | 0.95 | HPGD (0.61) | HPGDHIF1AEPAS1ALDH1A1HRH3 | |
| SCHEMBL28137072 | 0.92 | HPGD (0.58) | HPGDHIF1AEPAS1ALDH1A1HRH3 | |
| SCHEMBL3013949 | 0.92 | SMN1; SMN2 (0.59) | HPGDHIF1AEPAS1ALDH1A1HRH3 | |
| SCHEMBL3022342 | 0.91 | HPGD (0.57) | HPGDHIF1AEPAS1ALDH1A1HRH3 | |
| SCHEMBL255145 | 0.91 | MMP13 (0.57) | HPGDHIF1AEPAS1ALDH1A1 | |
| SCHEMBL13266914 | 0.91 | HIF1A (0.60) | HPGDHIF1AEPAS1ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 693 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890677-B1 | N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-11-15 | — | — | EP | claimed |
| EP-1313703-B1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | claimed |
| EP-1313703-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | claimed |
| US-6407235-B1 | A NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR-SUBTYPE SELECTIVE BLOCKERS; PRODRUGS HAVE IMPROVED SOLUBILITY AND ARE HYDROLYZED IN VIVO; FOR EXAMPLE, THE 4-AMINOMETHYL-BENZOIC ACID ESTER OF THE PHENOL, OR THE PHOSPHATE ESTER | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | claimed |
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | EVOTEC INTERNATIONAL GMBH (DE) | 2002-04-04 | — | — | US | claimed |
| WO-2002016321-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | claimed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | claimed |
| EP-0604368-B1 | Anti retroviral hydrazine derivatives | CIBA GEIGY AG (CH) | 1996-09-18 | — | — | EP | claimed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | claimed |
| US-4305940-A | Benzamides with local anaesthetic and antiarrhythmic activity, salts, and method of preparation thereof and pharmaceutical compositions therefrom | B.B.R. BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1981-12-15 | — | — | US | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| US-12459970-B2 | Progesterone analogs and uses related thereto | EMORY UNIVERSITY (US) | 2025-11-04 | — | — | US | disclosed |
| US-12415829-B2 | Progesterone phosphate analogs and uses related thereto | EMORY UNIVERSITY (US) | 2025-09-16 | — | — | US | disclosed |
| US-12391706-B2 | Multi-target tyrosine kinase inhibitor | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| EP-0584192-A1 | PRODRUG ESTERS OF PHENOLIC 2-PIPERIDINO-1-ALKANOLS | PFIZER INC. (US) | 1994-03-02 | — | — | EP | disclosed |
| EP-0539372-A1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1993-05-05 | — | — | EP | disclosed |
| CN-1065866-A | The prodrug esters of phenol 2-piperidino-(1-position only)-1-alkanol | PFIZER (US) | 1992-11-04 | — | — | CN | disclosed |
| WO-1992018502-A1 | PRODRUG ESTERS OF PHENOLIC 2-PIPERIDINO-1-ALKANOLS | PFIZER INC. (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1991011448-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1991-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | HAO2, CYP2B6, CBR1 | HPGD 299/4885HIF1A 382/4885EPAS1 2409/4885 |
| US-12391706-B2 | Multi-target tyrosine kinase inhibitor | LCK, ABL1, DSTYK | HPGD 3410/4885HIF1A 3231/4885EPAS1 3082/4885 |
| US-12415829-B2 | Progesterone phosphate analogs and uses related thereto | PGR, SHBG, PGRMC2 | HPGD 232/4885HIF1A 358/4885EPAS1 2249/4885 |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | ROCK1, RHOC, ROCK2 | HPGD 369/4885HIF1A 1132/4885EPAS1 1754/4885 |
| US-12459970-B2 | Progesterone analogs and uses related thereto | PGR, SHBG, PGRMC1 | HPGD 151/4885HIF1A 235/4885EPAS1 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.